Technical Specifications
• PHH from pooled male/female donors
• Co-culture with Kupffer cells and LECs
• Guaranteed 28 days viability
• 96-well format, 1 microtissue per well
• Delivered with min. 50 mL of 3D InSight™ Liver Maintenance Medium (larger quantities available on request)
• Biweekly production ensures our microtissues are ready when you are
Product Advantages
• Reflect the average response of a population with a model incorporating hepatocytes from 5 male and 5 female donors
• Achieve the highest biological relevance in an in vitro model with primary hepatocyte, Kupffer cell, and liver endothelial cell (LEC) co-cultures
• Test long-term effects of drug exposure in an organotypic, functional liver model
• Highly reproducible and robust liquid handling in InSphero’s patented Akura™ 96 plates (protects microtissues from accidental aspiration)
• Complete turnkey solutions offers lower cost-of-ownership than in-house production
Pharma-Validated in Genentech and AstraZeneca Study
A landmark Archives of Toxicology article, “Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury” by our collaborators Will Proctor, Alison Foster, Simon Messner, Dominic Williams and several other notable experts in the field, highlights the advantages of using 3D InSight™ Human Liver Microtissues for DILI prediction.